TUESDAY, May 10 (HealthDay News) -- Scientists have developed a
new, albeit preliminary, genetic test that seems to predict which
breast cancer patients can benefit from specific types of
That, in turn, could greatly help guide treatment, according to
a study in the May 11 issue of the
Journal of the American Medical Association.
The findings are exciting but need to be replicated, said one
expert, Dr. Iuliana Shapira, director of cancer genetics at Monter
Cancer Center and assistant professor of medicine at Hofstra
University North Shore Long Island Jewish Health System in Lake
Success, NY. She was not involved in the study.
According to the study's lead author, Dr. W. Fraser Symmans,
gene-based tests such as the Oncotype DX are already in wide used
to help guide breast cancer care. That test can help predict a
patient's chance for breast cancer recurrence, but only if they
have estrogen-receptor-positive breast tumor and are treated with
hormone therapy, said Symmans, who is professor of pathology at the
University of Texas MD Anderson Cancer Center in Houston.
Based on the results of Oncotype DX, "patients with low risk
might [be able to] avoid chemotherapy," he said.
The new study looked at a newer "genomic predictor" of breast
cancer treatment response and survival for women with newly
diagnosed, invasive breast cancer. The study was based on tumor
samples taken from 310 patients with HER2/neu-negative breast
cancer who were treated sequentially with two chemotherapy drugs,
taxane and anthracyline, both common components of breast cancer
If the tumors were estrogen-receptor (ER)-positive (meaning
their tumors responded to estrogen), the women were also treated
with hormonal (endocrine) therapy.
The new test appeared to be effective in predicting outcomes: 92
percent of the women that the test predicted would respond to this
chemotherapy did, in fact, survive three years without a relapse,
giving them an 18 percent lower risk of dying compared to those
identified as "non-responders" to the treatment.
And, Symmans said, "at three years, breast cancer had not
returned in 97 percent of women with ER-positive and 83 percent of
women with triple-(ER) negative breast cancer if they were
predicted to be treatment-sensitive. If they were predicted to be
treatment-insensitive, the rates were 86 percent and 57 percent,
The study was funded by Susan G. Komen for the Cure and the U.S.
National Cancer Institute, among others. Several of the authors
also hold patents with Nuvera Biosciences, Inc., which was involved
in the test.
"This study is not the definitive final word on the subject, but it offers a totally new way of looking at the question of how do we predict whose tumor is really sensitive to chemotherapy, whose tumor is probably resistant to chemo or neither of the above," said Symmans.
One expert called the study just one "baby step" on the path
towards more individualized treatments for patients. "I don't know
if this is enough to propel people to use this," said Dr. Stephanie
Bernik, chief of surgical oncology at Lenox Hill Hospital in New
The test, while promising, is "not ready for patients," agreed
Dr. Massimo Cristofanilli, professor and chairman of medical
oncology at Fox Chase Cancer Center in Philadelphia. Nor does it
predict which therapy will be best, he added.
But depending on further research, the test may one day be
valuable in helping women and their doctors make difficult
decisions regarding treatment, as opposed to today, when so much is
guesswork. "It's important to me to not give to have to give 100
women chemotherapy to save 10 or 15 lives," Shapira explained.
"It's important to me to be able to identify the 10 or 15 patients
who are going to benefit from chemotherapy."
There's more on treatments for breast cancer at the
U.S. National Cancer Institute.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.